Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc    MRK


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck & Co., Inc : Good timing to go long again

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2020 | 09:15am EDT
long trade
Entry price : 70.17$ | Target : 77.7$ | Stop-loss : 65.9$ | Potential : 10.73%
The medium term support area around 66.4 USD should allow Merck & Co., Inc shares to re-establish an upward trend in the short term.
Investors have an opportunity to buy the stock and target the $ 77.7.
Merck & Co., Inc : Merck & Co., Inc : Good timing to go long again
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • Merck & Co., Inc accounts for 4.70 % of our USA Portfolio. A trade is currently open since 10/23/2019 with a purchase price of $ 81.81. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.

  • The share is getting closer to its long-term support in weekly data, at USD 66.58, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 66.4 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

  • The company's earnings releases usually do not meet expectations.
  • The company's enterprise value to sales, at 3.79 times its current sales, is high.
  • The underlying tendency is negative on the weekly chart below the resistance at 79.73 USD
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK & CO., INC-21.13%181 927
JOHNSON & JOHNSON-15.57%324 693
ROCHE HOLDING AG-5.53%264 026
NOVARTIS-17.30%180 007
PFIZER, INC.-21.13%171 422
NOVO NORDISK A/S-1.01%133 274
AMGEN INC.-17.75%116 941
ASTRAZENECA PLC-10.54%110 838
ABBVIE INC.-17.92%107 310
More Results

David Meurisse
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 49 729 M
EBIT 2020 17 877 M
Net income 2020 13 089 M
Debt 2020 15 700 M
Yield 2020 3,36%
P/E ratio 2020 14,0x
P/E ratio 2021 12,2x
EV / Sales2020 3,97x
EV / Sales2021 3,71x
Capitalization 182 B
Income Statement Evolution
Mean consensus BUY
Number of Analysts 20
Average target price 96,32  $
Last Close Price 71,73  $
Spread / Highest target 49,2%
Spread / Average Target 34,3%
Spread / Lowest Target 19,9%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director